The oncology therapy developer has filed for an IPO just two years after emerging from stealth to advance Harvard and Stanford research.

Centessa, formed earlier this year through a ten-way merger involving multiple spinouts, has completed a listing in the US.

Zymergen has purchased Lodo Therapeutics, which is advancing Rockefeller research, for an undisclosed sum five years after the company raised its only funding round.

UC San Francisco spinout Effector Therapeutics is set to go public through a reverse merger with Locust Walk Acquisition Corp that includes a $60m PIPE financing.

Columbia’s Text IQ has been bought by Relativity for an undisclosed amount.

Lund spinout Glō has agreed to an acquisition by Nanosys, which will now look to strengthen its market share in TV sets and enter more markets such as AR.

IP Group is exiting the diffractive waveguide producer in a cash-and-share purchase by Snap.

The Lund research-based oat milk brand has floated in a $1.43bn IPO on the Nasdaq Global Select Market after pricing shares at $17.

SUNY Polytechnic University-backed Norsk Titanium has begun trading on Euronext Growth Oslo.

Yale's immunological disease treatment developer floated its shares below its initial price range in an IPO in the US.